Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Axsome Thera (AXSM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 273,358
  • Shares Outstanding, K 29,813
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,940 K
  • 36-Month Beta 3.41
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 325.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -17.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.63 +22.28%
on 01/29/19
10.80 -13.61%
on 02/06/19
+1.39 (+17.51%)
since 01/15/19
3-Month
1.94 +380.93%
on 12/27/18
10.80 -13.61%
on 02/06/19
+6.36 (+214.14%)
since 11/15/18
52-Week
1.94 +380.93%
on 12/27/18
10.80 -13.61%
on 02/06/19
+6.73 (+258.85%)
since 02/15/18

Most Recent Stories

More News
Biotechnology Companies See Growth in Optic Treatment Sectors

The vast number of people in need of medical treatment has grown tremendously over the years. Some cases are a result of environmental changes, yet others can be caused by genetics. Regardless, there is...

QBIO : 2.0400 (+0.99%)
AERI : 41.75 (+1.66%)
NVS : 89.88 (+0.97%)
VSTM : 3.30 (+7.14%)
AXSM : 9.33 (+1.74%)
Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine

FDA agreement achieved on Phase 3 trial design, endpoints, and statistical approach

AXSM : 9.33 (+1.74%)
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy

Topline results anticipated in 2Q 2019

AXSM : 9.33 (+1.74%)
Why Clinical Trial Advantages and Regulatory Process in EU may Hold Advantages Over the U.S.

Financialnewsmedia.com News Commentary

LJPC : 6.23 (+4.88%)
MRNA : 21.44 (+9.05%)
PFE : 42.40 (+1.02%)
MBRX : 1.47 (unch)
AXSM : 9.33 (+1.74%)
Market Rally Extends to Biotech

HENDERSON, NV / ACCESSWIRE / January 9, 2019 / Markets are rallying in first full market week of 2019 and the biotech sector is responding as many oversold small caps are starting to rebound. We've found...

AXON : 1.22 (-5.43%)
AXSM : 9.33 (+1.74%)
This Stock Generated 25X Returns In Just Five Years: Could BTCY Be At The Same Crossroads?

The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few subsectors have benefitted more than...

BTCY : 1.0500 (-1.87%)
AXSM : 9.33 (+1.74%)
The Next Big Biotech Breakout

HENDERSON, NV / ACCESSWIRE / January 8, 2019 / Celgene's major deal with Bristol-Myers Squibb seems to have woken up the sleeping giant that is the biotech market. Axsome announced positive trial data...

GNMX : 0.23 (-6.12%)
ENDV : 0.0234 (+5.41%)
CELGZ : 0.91 (+7.06%)
HSGX : 0.13 (unch)
BMY : 51.67 (+1.65%)
AXSM : 9.33 (+1.74%)
Thinking about buying stock in Apple, Axsome Therapeutics, Luxoft, Netflix or QEP Resources?

InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, LXFT, NFLX, and QEP.

NFLX : 356.87 (-0.61%)
AAPL : 170.42 (-0.22%)
LXFT : 58.23 (unch)
QEP : 8.37 (+1.58%)
AXSM : 9.33 (+1.74%)
Portfolios Making Up For Lost Time

Portfolios Making Up For Lost Time

SCVL : 37.33 (+2.92%)
TGNA : 12.27 (+0.25%)
FOSL : 14.88 (-2.43%)
HCA : 144.26 (+1.43%)
GPRO : 5.99 (+3.45%)
TSCO : 97.58 (+1.88%)
HTZ : 17.22 (+0.82%)
AXSM : 9.33 (+1.74%)
AAP : 169.99 (+0.74%)
TMUS : 72.05 (+2.20%)
SGMO : 8.79 (-2.33%)
AOBC : 12.66 (+2.43%)
LULU : 151.09 (-2.43%)
SEE : 42.15 (+0.12%)
RH : 145.05 (+1.16%)
RCII : 17.96 (+0.84%)
MTSI : 17.77 (+2.30%)
SPLK : 136.25 (+1.28%)
JACK : 80.27 (+0.83%)
ERI : 47.68 (+0.34%)
WMT : 99.99 (+1.49%)
MDU : 26.25 (unch)
Axsome Therapeutics Raises $23.3 Million Under Existing ATM Facility

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, announced that today it raised...

AXSM : 9.33 (+1.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade AXSM with:

Business Summary

Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc....

See More

Key Turning Points

2nd Resistance Point 10.17
1st Resistance Point 9.75
Last Price 9.33
1st Support Level 9.06
2nd Support Level 8.79

See More

52-Week High 10.80
Last Price 9.33
Fibonacci 61.8% 7.42
Fibonacci 50% 6.37
Fibonacci 38.2% 5.32
52-Week Low 1.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar